Ionis Pharmaceuticals Inc (NASDAQ: IONS) has reported a loss for its third fiscal quarter (ending September 30) of $-0.95 versus a loss $-1.03 for the same period a year ago — a decline of -8%. E.P.S. were $-2.44 for the latest four quarters through September 30 versus $-2.87 for the same period a year ago — a decline of -15%.
Recent Price Action
Ionis Pharmaceuticals Inc (NASDAQ: IONS) stock closed at $39.04 on 11/6/24 after a modest gain of 0.6%. Trading volume in this advance was normal. The stock has performed in line with the market over the last nine months and has declined -1.7% during the last week.
Current PriceTarget Research Rating
IONS is expected to continue to be a modest Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Ionis Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Ionis Pharmaceuticals has a neutral Power Rating of 49 but a very low Appreciation Score of 4, with the Lowest Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment